TNSN04159A1 - Synthese controlee de ziprasidone et compositions en contenant - Google Patents

Synthese controlee de ziprasidone et compositions en contenant

Info

Publication number
TNSN04159A1
TNSN04159A1 TNP2004000159A TNSN04159A TNSN04159A1 TN SN04159 A1 TNSN04159 A1 TN SN04159A1 TN P2004000159 A TNP2004000159 A TN P2004000159A TN SN04159 A TNSN04159 A TN SN04159A TN SN04159 A1 TNSN04159 A1 TN SN04159A1
Authority
TN
Tunisia
Prior art keywords
ziprasidone
compositions containing
containing same
controlled synthesis
chloroziprasidone
Prior art date
Application number
TNP2004000159A
Other languages
English (en)
Inventor
Frank Robert Busch
Kyle Robert Leeman
Harry Ralph Howard Jr
Adam Worth Grobin
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27761437&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN04159(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN04159A1 publication Critical patent/TNSN04159A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La présente invention propose une composition de ziprasidone qui comprend une quantité non supérieure à 1000 ppm de des- chloroziprasidone; avantageusement non supérieur à environ 500 ppm de des chloroziprasidone; et plus avantageusement non supérieur à environ 100 ppm de des- chloroziprasidone. Des procédés pour la synthèse et l'utilisation de ces compositions de ziprasidone sont également proposés.
TNP2004000159A 2002-02-20 2004-08-19 Synthese controlee de ziprasidone et compositions en contenant TNSN04159A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35880602P 2002-02-20 2002-02-20
US35903802P 2002-02-21 2002-02-21
US36045902P 2002-02-27 2002-02-27
PCT/IB2003/000642 WO2003070246A1 (fr) 2002-02-20 2003-02-17 Synthese controlee de ziprasidone et ses compositions

Publications (1)

Publication Number Publication Date
TNSN04159A1 true TNSN04159A1 (fr) 2007-03-12

Family

ID=27761437

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000159A TNSN04159A1 (fr) 2002-02-20 2004-08-19 Synthese controlee de ziprasidone et compositions en contenant

Country Status (41)

Country Link
EP (1) EP1476162B1 (fr)
JP (1) JP4554938B2 (fr)
KR (1) KR100773622B1 (fr)
CN (2) CN101735212A (fr)
AP (1) AP2004003103A0 (fr)
AR (1) AR038563A1 (fr)
AT (1) ATE359787T1 (fr)
AU (2) AU2003206035A1 (fr)
BR (1) BR0307833A (fr)
CA (1) CA2475302C (fr)
CO (1) CO5611138A2 (fr)
CY (1) CY1106467T1 (fr)
DE (1) DE60313289T2 (fr)
DK (1) DK1476162T3 (fr)
EA (1) EA007866B1 (fr)
EC (1) ECSP045239A (fr)
ES (1) ES2283745T3 (fr)
GE (1) GEP20074030B (fr)
GT (1) GT200300040A (fr)
HR (1) HRP20040711A2 (fr)
IL (1) IL163277A (fr)
IS (1) IS7344A (fr)
MA (1) MA27177A1 (fr)
MX (1) MXPA04006993A (fr)
MY (1) MY139523A (fr)
NO (2) NO20043902L (fr)
NZ (1) NZ534443A (fr)
OA (1) OA12774A (fr)
PA (1) PA8567001A1 (fr)
PE (1) PE20030942A1 (fr)
PL (1) PL372238A1 (fr)
PT (1) PT1476162E (fr)
RS (1) RS60404A (fr)
SI (1) SI1476162T1 (fr)
SV (1) SV2004001485A (fr)
TN (1) TNSN04159A1 (fr)
TW (1) TW200307546A (fr)
UA (1) UA77057C2 (fr)
UY (1) UY27668A1 (fr)
WO (1) WO2003070246A1 (fr)
ZA (1) ZA200406276B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066521A1 (fr) 2000-03-06 2001-09-13 Acadia Pharmaceuticals, Inc. Composes azacycliques utilises dans le traitement de maladies liees a la serotonine
WO2003057698A2 (fr) 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine
IL165907A0 (en) 2002-06-24 2006-01-15 Acadia Pharm Inc N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2004050655A1 (fr) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Formes polymorphes de ziprasidone et son chlorhydrate
AU2003300814A1 (en) 2002-12-04 2004-06-23 Dr. Reddy's Laboratories Inc. Polymorphic forms of ziprasidone and its hydrochloride
PT1587789E (pt) 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
WO2004083192A1 (fr) 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd. Formes polymorphes de valsartan
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
WO2004094392A1 (fr) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Processus de preparation de valsartan
WO2005016325A2 (fr) 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. Chlorhydrate de ziprasidone cristallin et ses procedes de preparation
CA2543805A1 (fr) 2003-10-24 2005-05-06 Gideon Pilarsky Procedes de preparation de ziprasidone
US20050197347A1 (en) * 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
ATE451367T1 (de) 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
CA2467538C (fr) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. Nouveau chlorhydrate de ziprasidone amorphe (chlorhydrate de 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydr o-2h-indol-2-one) et procedes pour sa production
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
CA2471219A1 (fr) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Preparation amelioree d'une forme anhydre du chlorhydrate de 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one (chlorhydrate de ziprasidone)
CN101035759B (zh) 2004-09-27 2011-06-15 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐的合成和晶形
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
ES2250000B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Procedimiento para la preparacion de ziprasidona.
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
EP1841764A1 (fr) * 2005-01-27 2007-10-10 Hetero Drugs Limited Procédé de synthèse de la ziprasidone impliquant
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
CN100491375C (zh) * 2006-07-01 2009-05-27 浙江美诺华药物化学有限公司 一种齐拉西酮的制备方法
ES2423485T3 (es) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
CN102234272A (zh) * 2010-04-21 2011-11-09 上海医药工业研究院 盐酸齐拉西酮半水合物的制备方法
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (fr) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Association de pimavansérine et de modulateurs du cytochrome p450
EP3558311A1 (fr) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavansérine seule ou en association pour une utilisation dans le traitement de la psychose liée à la maladie d'alzheimer
CN108239085A (zh) * 2016-12-26 2018-07-03 四川科瑞德凯华制药有限公司 一种甲磺酸齐拉西酮的纯化及制备方法
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN112724066B (zh) * 2021-02-04 2022-10-21 海南鑫开源医药科技有限公司 一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法
CN116046966A (zh) * 2023-01-17 2023-05-02 北京协和建昊医药技术开发有限责任公司 一种流动相配置装置及其配置方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
CN1071324C (zh) 1995-11-07 2001-09-19 辉瑞大药厂 制备3-(1-哌嗪基)-1,2-苯并异噻唑的方法和中间体
SI0904273T1 (en) * 1996-05-07 2003-08-31 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
PA8567001A1 (es) 2003-12-10
NO20043902L (no) 2004-09-17
EA200400815A1 (ru) 2004-12-30
SV2004001485A (es) 2004-05-07
CA2475302A1 (fr) 2003-08-28
JP2005525347A (ja) 2005-08-25
ECSP045239A (es) 2004-09-28
TW200307546A (en) 2003-12-16
MY139523A (en) 2009-10-30
ES2283745T3 (es) 2007-11-01
JP4554938B2 (ja) 2010-09-29
GT200300040A (es) 2007-01-12
OA12774A (en) 2006-07-04
KR20040086417A (ko) 2004-10-08
DK1476162T3 (da) 2007-07-02
DE60313289D1 (de) 2007-05-31
MA27177A1 (fr) 2005-01-03
AU2009202008A1 (en) 2009-06-11
UA77057C2 (en) 2006-10-16
UY27668A1 (es) 2003-10-31
MXPA04006993A (es) 2004-11-10
IL163277A (en) 2010-05-31
PT1476162E (pt) 2007-06-25
PL372238A1 (en) 2005-07-11
DE60313289T2 (de) 2007-12-27
AR038563A1 (es) 2005-01-19
IS7344A (is) 2004-07-05
KR100773622B1 (ko) 2007-11-05
HRP20040711A2 (en) 2004-12-31
PE20030942A1 (es) 2003-11-08
NO20100584L (no) 2004-09-17
CA2475302C (fr) 2009-05-12
GEP20074030B (en) 2007-02-12
AU2003206035A1 (en) 2003-09-09
ZA200406276B (en) 2005-09-20
ATE359787T1 (de) 2007-05-15
WO2003070246A1 (fr) 2003-08-28
CO5611138A2 (es) 2006-02-28
AP2004003103A0 (en) 2004-09-30
EP1476162B1 (fr) 2007-04-18
BR0307833A (pt) 2004-12-07
SI1476162T1 (sl) 2007-08-31
CY1106467T1 (el) 2012-01-25
EP1476162A1 (fr) 2004-11-17
EA007866B1 (ru) 2007-02-27
CN1635892A (zh) 2005-07-06
NZ534443A (en) 2007-07-27
RS60404A (en) 2006-10-27
CN101735212A (zh) 2010-06-16

Similar Documents

Publication Publication Date Title
TNSN04159A1 (fr) Synthese controlee de ziprasidone et compositions en contenant
MA28469B1 (fr) Inhibiteurs de la dipeptidyle peptidase
MA27058A1 (fr) Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino) ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene) methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes pour leur preparation et compositions les contenant
EA200100519A1 (ru) Композиции на основе тонкоизмельченного эплеренона
DE69816280D1 (de) Inhibitoren des impdh-enzyms
DE69939165D1 (de) N,n-disubstituierte amide welche die bindung von integrinen an ihre rezeptoren hemmen
ATE191334T1 (de) Hydrophilierte zahnabdruckmassen
WO2003086303A3 (fr) Agonistes de recepteur active frx (farnesoid x receptor)
GB0031103D0 (en) Chemical compounds
MXPA04004515A (es) Mejoras referentes a articulos para limpieza de inodoro.
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
MA26770A1 (fr) Diarylamines substituees par 1-heterocycle.
NO996578L (no) Urokinase-inhibitorer
PL1689232T3 (pl) Sposób ochrony materiałów
ATE413388T1 (de) Muskarin antagonisten
DE60323942D1 (de) Lipase-hemmende zusammensetzung
IL126542A0 (en) Cytoprotective compounds
IL117209A0 (en) 1-aryl-2-acylamino-ethane compounds and pharmaceutical compositions containing them
DE60215368D1 (de) Pyranderivate als inhibitoren von ace und nep
ES2195306T3 (es) Composiciones de blanqueo.
DK1474183T3 (da) Vandigt middel til hudvenlig behandling af florstoffer
DE59303446D1 (de) Neue bis-phenyl-hexene
SI1651596T1 (sl) Novi derivati ditiobis aminobutan sulfonatov in sestavki ki jih vsebujejo
ATE358675T1 (de) Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol
MY117392A (en) Monocyclic compounds with four bifunctional residues having nk-2 antagonist action